Innovation Pharmaceuticals Inc (IPIX)

[georgejjl]

“To date, the trial has exceeded our expectations on all fronts. The study needs to be successfully completed with the final data fully analyzed, but at this point we attribute the early favorable results to Brilacidin’s robust anti-inflammatory therapeutic profile. Given Brilacidin’s unique mechanism of action, the body is able to get back to doing what it’s usually already good at—fighting illness and infection,” said Arthur P. Bertolino, MD, PhD, MBA, President and Chief Medical Officer at Cellceutix.

Regarding the Brilacidin Phase 2 trial for mild-to-moderate ulcerative proctitis/ulcerative proctosigmoiditis.

http://www.cellceutix.com/press-release/2017/1/17/cellceutix-completes-enrollment-in-second-of-three-planned-cohorts-in-phase-2-clinical-trial-of-brilacidin-for-inflammatory-bowel-disease

Cohort 2 interim results due within 2 weeks.

Good luck and GOD bless,

George